Vaccinomics: Paving the Way for Personalized Immunization


Цитировать

Полный текст

Аннотация

Vaccines are one of the most important medical advancements in human history. They have been successfully used to control and limit the spread of many of the lethal diseases that have plagued us, such as smallpox and polio. Previous vaccine design methodologies were based on the model of \"isolate-inactivate inject\", which amounts to giving the same vaccine dose to everyone susceptible to infection. In recent years, the importance of how the host genetic background alters vaccine response necessitated the introduction of vaccinomics, which is aimed at studying the variability of vaccine efficacy by associating genetic variability and immune response to vaccination. Despite the rapid developments in variant screening, data obtained from association studies is often inconclusive and cannot be used to guide the new generation of vaccines. This review aims to compile the polymorphisms in HLA and immune system genes and examine the link with their immune response to vaccination. The compiled data can be used to guide the development of new strategies for vaccination for vulnerable groups. Overall, the highly polymorphic HLA locus had the highest correlation with vaccine response variability for most of the studied vaccines, and it was linked to variation in multiple stages of the immune response to the vaccines for both humoral and cellular immunity. Designing new vaccine technologies and immunization regiments to accommodate for this variability is an important step for reaching a vaccinomics-based approach to vaccination

Ключевые слова

Об авторах

Laith Al-Eitan

Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology

Автор, ответственный за переписку.
Email: info@benthamscience.net

Moh’d. ElMotasem

Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology

Email: info@benthamscience.net

Iliya Khair

Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology

Email: info@benthamscience.net

Saif Alahmad

Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology

Email: info@benthamscience.net

Список литературы

  1. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc Bayl Univ Med Cent 2005; 18(1): 21-5. doi: 10.1080/08998280.2005.11928028 PMID: 16200144
  2. Smatti MK, Alkhatib HA, Al Thani AA, Yassine HM. Will host genetics affect the response to SARS-CoV-2 vaccines? Historical precedents. Front Med 2022; 9: 802312. doi: 10.3389/fmed.2022.802312 PMID: 35360730
  3. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: A review. Vaccine 2018; 36(36): 5350-7. doi: 10.1016/j.vaccine.2017.07.062 PMID: 28774561
  4. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: The role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 2007; 82(6): 653-64. doi: 10.1038/sj.clpt.6100415 PMID: 17971814
  5. Kennedy RB, Ovsyannikova IG, Haralambieva IH, Lambert ND, Pankratz VS, Poland GA. Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients. Immunogenetics 2014; 66(7-8): 493-9. doi: 10.1007/s00251-014-0776-3 PMID: 24811271
  6. Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, Poland GA. The genetic basis for interindividual immune response variation to measles vaccine: New understanding and new vaccine approaches. Expert Rev Vaccines 2013; 12(1): 57-70. doi: 10.1586/erv.12.134 PMID: 23256739
  7. Lee J, Arun Kumar S, Jhan YY, Bishop CJ. Engineering DNA vaccines against infectious diseases. Acta Biomater 2018; 80: 31-47. doi: 10.1016/j.actbio.2018.08.033 PMID: 30172933
  8. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines a new era in vaccinology. Nat Rev Drug Discov 2018; 17(4): 261-79. doi: 10.1038/nrd.2017.243 PMID: 29326426
  9. Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel) 2014; 2(3): 624-41. doi: 10.3390/vaccines2030624 PMID: 26344749
  10. Saliou P. Live vaccines. Rev Prat 1995; 45(12): 1492-6. PMID: 7660002
  11. Barbara Sanders MK. Inactivated viral vaccines. SpringerLink 2015; pp. 45-80. doi: 10.1007/978-3-662-45024-6_2
  12. Weinshilboum RM, Wang L. Pharmacogenomics: Precision medicine and drug response. Mayo Clin Proc 2017; 92(11): 1711-22. doi: 10.1016/j.mayocp.2017.09.001 PMID: 29101939
  13. Tripathi P, Singh J, Lal JA, Tripathi V. Next generation sequencing: An emerging tool for drug designing. Curr Pharm Des 2019; 25(31): 3350-7. doi: 10.2174/1381612825666190911155508 PMID: 31544713
  14. Luciani F, Bull RA, Lloyd AR. Next generation deep sequencing and vaccine design: Today and tomorrow. Trends Biotechnol 2012; 30(9): 443-52. doi: 10.1016/j.tibtech.2012.05.005 PMID: 22721705
  15. Le T, Sun C, Chang J, Zhang G, Yin X. mRNA vaccine development for emerging animal and zoonotic diseases. Viruses 2022; 14(2): 401. doi: 10.3390/v14020401 PMID: 35215994
  16. Fortner A, Bucur O. mRNA-based vaccine technology for HIV. Discoveries 2022; 10(2): e150. doi: 10.15190/d.2022.9 PMID: 36438441
  17. Hogan MJ, Pardi N. mRNA vaccines in the COVID-19 pandemic and beyond. Annu Rev Med 2022; 73(1): 17-39. doi: 10.1146/annurev-med-042420-112725 PMID: 34669432
  18. Pardi N. mRNA innovates the vaccine field. Vaccines 2021; 9(5): 486. doi: 10.3390/vaccines9050486 PMID: 34064557
  19. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. Nat Rev Drug Discov 2021; 20(11): 817-38. doi: 10.1038/s41573-021-00283-5 PMID: 34433919
  20. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol 2012; 9(11): 1319-30. doi: 10.4161/rna.22269 PMID: 23064118
  21. Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther 2021; 28(3-4): 117-29. doi: 10.1038/s41434-020-00204-y PMID: 33093657
  22. Nilsson LJ, Regnström KJ. Pharmacogenomics in the evaluation of efficacy and adverse events during clinical development of vaccines. Methods Mol Biol 2008; 448: 469-79. doi: 10.1007/978-1-59745-205-2_17 PMID: 18370243
  23. Al-Eitan L, Haddad Y. Emergence of pharmacogenomics in academic medicine and public health in Jordan: History, present state and prospects. Curr Pharmacogenomics Person Med 2015; 12(3): 167-75. doi: 10.2174/1875692113666150115221210
  24. AL-Eitan L, Tarkhan A. Practical challenges and translational issues in pharmacogenomics and personalized medicine from 2010 onwards. Curr Pharmacogenomics Person Med 2017; 14(1): 7-17. doi: 10.2174/1875692115666161215103842
  25. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. BMJ 1960; 2(5197): 485-91. doi: 10.1136/bmj.2.5197.485 PMID: 13820968
  26. Evans DA, Storey PB, McKusick VA. Further observations on the determination of the isoniazid inactivator phenotype. Bull Johns Hopkins Hosp 1961; 108: 60-6. PMID: 13697555
  27. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009; 10(5): 837-52. doi: 10.2217/pgs.09.25 PMID: 19450131
  28. Poland GA, Ovsyannikova IG, Kennedy RB. Pharmacogenomics and vaccine development. Clin Pharmacol Ther 2021; 110(3): 546-8. doi: 10.1002/cpt.2288 PMID: 34097754
  29. Poland GA, Kennedy RB, McKinney BA, et al. Vaccinomics, adversomics, and the immune response network theory: Individualized vaccinology in the 21st century. Semin Immunol 2013; 25(2): 89-103. doi: 10.1016/j.smim.2013.04.007 PMID: 23755893
  30. Thomas C, Moridani M. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology 2010; 278(2): 204-10. doi: 10.1016/j.tox.2009.10.008 PMID: 19837123
  31. Kimman TG, Vandebriel RJ, Hoebee B. Genetic variation in the response to vaccination. Public Health Genomics 2007; 10(4): 201-17. doi: 10.1159/000106559 PMID: 17895626
  32. Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev 2019; 32(2): e00084-18. doi: 10.1128/CMR.00084-18 PMID: 30867162
  33. Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist C-A, Marchant A. Genetic regulation of immune responses to vaccines in early life. Genes Immun 2004; 5(2): 122-9. doi: 10.1038/sj.gene.6364051 PMID: 14737096
  34. Höhler T, Reuss E, Freitag CM, Schneider PM. A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. Hepatology 2005; 42(1): 72-6. doi: 10.1002/hep.20740 PMID: 15918171
  35. Khan T, Khan A, Wei DQ. MMV-db: Vaccinomics and RNA-based therapeutics database for infectious hemorrhagic fever-causing mammarenaviruses. Database 2021; 2021: baab063. doi: 10.1093/database/baab063 PMID: 34679165
  36. Khan A, Khan S, Ahmad S, et al. HantavirusesDB: Vaccinomics and RNA-based therapeutics database for the potentially emerging human respiratory pandemic agents. Microb Pathog 2021; 160: 105161. doi: 10.1016/j.micpath.2021.105161 PMID: 34461244
  37. Khan T, Khan A, Nasir SN, Ahmad S, Ali SS, Wei DQ. CytomegaloVirusDb: Multi-omics knowledge database for cytomegaloviruses. Comput Biol Med 2021; 135: 104563. doi: 10.1016/j.compbiomed.2021.104563 PMID: 34256256
  38. Vlasova-St. Louis. COVID-19-Omics report: From individual omics approaches to precision medicine. Reports 2023; 6(4): 45. doi: 10.3390/reports6040045
  39. Wang D, Kumar V, Burnham KL, Mentzer AJ, Marsden BD, Knight JC. COMBATdb: A database for the COVID-19 multi-omics blood ATlas. Nucleic Acids Res 2023; 51(D1): D896-905. doi: 10.1093/nar/gkac1019 PMID: 36353986
  40. O’Connor D, Pollard AJ. Characterizing vaccine responses using host genomic and transcriptomic analysis. Clin Infect Dis 2013; 57(6): 860-9. doi: 10.1093/cid/cit373 PMID: 23728145
  41. Wang IM, Bett AJ, Cristescu R, Loboda A, ter Meulen J. Transcriptional profiling of vaccine‐induced immune responses in humans and non‐human primates. Microb Biotechnol 2012; 5(2): 177-87. doi: 10.1111/j.1751-7915.2011.00317.x PMID: 22103427
  42. Kennedy RB, Oberg AL, Ovsyannikova IG, Haralambieva IH, Grill D, Poland GA. Transcriptomic profiles of high and low antibody responders to smallpox vaccine. Genes Immun 2013; 14(5): 277-85. doi: 10.1038/gene.2013.14 PMID: 23594957
  43. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001; 27(3): 234-6. doi: 10.1038/85776 PMID: 11242096
  44. Al-Koofee D, Mubarak S. Genetic polymorphisms. IntechOpen 2020. doi: 10.5772/intechopen.88063
  45. RJ T. Forensic Medicine and Science, in Molecular Medicine. Amsterdam, Boston: Elsevier 2005; pp. 221-36.
  46. Yousefi S, Abbassi-Daloii T, Kraaijenbrink T, et al. A SNP panel for identification of DNA and RNA specimens. BMC Genomics 2018; 19(1): 90. doi: 10.1186/s12864-018-4482-7 PMID: 29370748
  47. Palmer LJ, Cardon LR. Shaking the tree: Mapping complex disease genes with linkage disequilibrium. Lancet 2005; 366(9492): 1223-34. doi: 10.1016/S0140-6736(05)67485-5 PMID: 16198771
  48. Schichman SA, Suess P, Vertino AM, Gray PS. Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment. Bone Marrow Transplant 2002; 29(3): 243-8. doi: 10.1038/sj.bmt.1703360 PMID: 11859397
  49. Lassaunière R, Tiemessen CT. FcγR genetic variation and HIV-1 vaccine efficacy: Context and considerations. Front Immunol 2021; 12: 788203. doi: 10.3389/fimmu.2021.788203 PMID: 34975881
  50. Degenhardt JD, de Candia P, Chabot A, et al. Copy number variation of CCL3-like genes affects rate of progression to simian-AIDS in Rhesus macaques (Macaca mulatta). PLoS Genet 2009; 5(1): e1000346. doi: 10.1371/journal.pgen.1000346 PMID: 19165326
  51. Pelak K, Need AC, Fellay J, et al. Copy number variation of KIR genes influences HIV-1 control. PLoS Biol 2011; 9(11): e1001208. doi: 10.1371/journal.pbio.1001208 PMID: 22140359
  52. Naranbhai V, Carrington M. Host genetic variation and HIV disease: From mapping to mechanism. Immunogenetics 2017; 69(8-9): 489-98. doi: 10.1007/s00251-017-1000-z PMID: 28695282
  53. Colucci M, De Santis E, Totti B, et al. Associations between allelic Variants of the human IgH 3′ regulatory region 1 and the immune response to BNT162b2 mRNA vaccine. Vaccines 2021; 9(10): 1207. doi: 10.3390/vaccines9101207 PMID: 34696315
  54. AL-Eitan LN, Alahmad SZ. Pharmacogenomics of genetic polymorphism within the genes responsible for SARS‐CoV‐2 susceptibility and the drug‐metabolising genes used in treatment. Rev Med Virol 2021; 31(4): e2194. doi: 10.1002/rmv.2194 PMID: 33205496
  55. AL-Eitan LN, Alahmad SZ. Allelic and genotypic analysis of the ACE I/D polymorphism for the possible prediction of COVID-19-related mortality and morbidity in Jordanian Arabs. J Biosaf Biosec 2023; 5(3): 89-95. doi: 10.1016/j.jobb.2023.07.005
  56. Li M, Wang H, Tian L, et al. COVID-19 vaccine development: Milestones, lessons and prospects. Signal Transduct Target Ther 2022; 7(1): 146. doi: 10.1038/s41392-022-00996-y PMID: 35504917
  57. Lombardi A, Bozzi G, Ungaro R, et al. Mini review immunological consequences of immunization with COVID-19 mRNA vaccines: Preliminary results. Front Immunol 2021; 12: 657711. doi: 10.3389/fimmu.2021.657711 PMID: 33777055
  58. Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination. Sci Immunol 2021; 6(58): eabi6950. doi: 10.1126/sciimmunol.abi6950 PMID: 33858945
  59. Turner JS, O’Halloran JA, Kalaidina E, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 2021; 596(7870): 109-13. doi: 10.1038/s41586-021-03738-2 PMID: 34182569
  60. Rogers CH, Mielczarek O, Corcoran AE. Dynamic 3D locus organization and its drivers underpin immunoglobulin recombination. Front Immunol 2021; 11: 633705. doi: 10.3389/fimmu.2020.633705 PMID: 33679727
  61. Gemmati D, Longo G, Gallo I, et al. Host genetics impact on SARS-CoV-2 vaccine-induced immunoglobulin levels and dynamics: The role of TP53, ABO, APOE, ACE2, HLA-A, and CRP genes. Front Genet 2022; 13: 1028081. doi: 10.3389/fgene.2022.1028081 PMID: 36531241
  62. Li M, Wei H, Zhong S, et al. Association of single nucleotide polymorphisms in LEP, LEPR, and PPARG with humoral immune response to influenza vaccine. Front Genet 2021; 12: 725538. doi: 10.3389/fgene.2021.725538 PMID: 34745208
  63. Moss AJ, Gaughran FP, Karasu A, et al. Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination. PLoS One 2013; 8(8): e71376. doi: 10.1371/journal.pone.0071376 PMID: 23951151
  64. Castrucci MR. Factors affecting immune responses to the influenza vaccine. Hum Vaccin Immunother 2018; 14(3): 637-46. doi: 10.1080/21645515.2017.1338547 PMID: 28617077
  65. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008; 26(Suppl 4) (4): D35-40. doi: 10.1016/j.vaccine.2008.07.065 PMID: 19230157
  66. Posteraro B, Pastorino R, Di Giannantonio P, et al. The link between genetic variation and variability in vaccine responses: Systematic review and meta-analyses. Vaccine 2014; 32(15): 1661-9. doi: 10.1016/j.vaccine.2014.01.057 PMID: 24513009
  67. Lei N, Li Y, Sun Q, et al. IFITM3 affects the level of antibody response after influenza vaccination. Emerg Microbes Infect 2020; 9(1): 976-87. doi: 10.1080/22221751.2020.1756696 PMID: 32321380
  68. Linnik JE, Egli A. Impact of host genetic polymorphisms on vaccine induced antibody response. Hum Vaccin Immunother 2016; 12(4): 907-15. doi: 10.1080/21645515.2015.1119345 PMID: 26809773
  69. Franco LM, Bucasas KL, Wells JM, et al. Integrative genomic analysis of the human immune response to influenza vaccination. eLife 2013; 2: e00299. doi: 10.7554/eLife.00299 PMID: 23878721
  70. Bucasas KL, Franco LM, Shaw CA, et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011; 203(7): 921-9. doi: 10.1093/infdis/jiq156 PMID: 21357945
  71. Meyer H, Ehmann R, Smith GL. Smallpox in the post-eradication era. Viruses 2020; 12(2): 138. doi: 10.3390/v12020138 PMID: 31991671
  72. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: Medical and public health management. JAMA 1999; 281(22): 2127-37. doi: 10.1001/jama.281.22.2127 PMID: 10367824
  73. World Health Organization. Global Commission for the Certification of Smallpox, E and O World Health, The global eradication of smallpox: Final report of the Global Commission for the Certification of Smallpox Eradication. Geneva: World Health Organization 1980.
  74. Kaynarcalidan O, Moreno Mascaraque S, Drexler I. Vaccinia virus: From crude smallpox vaccines to elaborate viral vector vaccine design. Biomedicines 2021; 9(12): 1780. doi: 10.3390/biomedicines9121780 PMID: 34944596
  75. Ovsyannikova IG, Kennedy RB, O’Byrne M, Jacobson RM, Pankratz VS, Poland GA. Genome-wide association study of antibody response to smallpox vaccine. Vaccine 2012; 30(28): 4182-9. doi: 10.1016/j.vaccine.2012.04.055 PMID: 22542470
  76. Ramamoorthy A, Kim HH, Shah-Williams E, Zhang L. Racial and ethnic differences in drug disposition and response: Review of new molecular entities approved between 2014 and 2019. J Clin Pharmacol 2022; 62(4): 486-93. doi: 10.1002/jcph.1978 PMID: 34608640
  77. Hepatitis. 2019. Available from: https://www.who.int/health-topics/hepatitis#tab=tab_1 cited 2019 Sep 1st
  78. Jeong SH, Lee HS. Hepatitis A: Clinical manifestations and management. Intervirology 2010; 53(1): 15-9. doi: 10.1159/000252779 PMID: 20068336
  79. Thuener J. Hepatitis A and B infections. Prim Care 2017; 44(4): 621-9. doi: 10.1016/j.pop.2017.07.005 PMID: 29132524
  80. Schwarz KB, Balistreri W. Viral hepatitis. J Pediatr Gastroenterol Nutr 2002; 35(1): S29-32. doi: 10.1097/00005176-200207001-00008 PMID: 12151818
  81. Chang M-H, Schwarz KB. Viral hepatitis in children: Prevention and management. SpringerLink 2019. doi: 10.1007/978-981-13-0050-9
  82. Wu JF, Chen CH, Ni YH, et al. Toll-like receptor and hepatitis B virus clearance in chronic infected patients: A long-term prospective cohort study in Taiwan. J Infect Dis 2012; 206(5): 662-8. doi: 10.1093/infdis/jis420 PMID: 22740716
  83. Höhler T, Reuss E, Evers N, et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: A vaccination study in twins. Lancet 2002; 360(9338): 991-5. doi: 10.1016/S0140-6736(02)11083-X PMID: 12383669
  84. Strebel PM. Measles vaccines, in Plotkin's vaccines. Elsevier 2018; pp. 579-618. doi: 10.1016/B978-0-323-35761-6.00037-7
  85. DeStefano F, Shimabukuro TT. The MMR vaccine and autism. Annu Rev Virol 2019; 6(1): 585-600. doi: 10.1146/annurev-virology-092818-015515 PMID: 30986133
  86. SA R. Mumps vaccines Plotkin’s vaccines. Elsevier 2018; pp. 663-88. doi: 10.1016/B978-0-323-35761-6.00039-0
  87. Reef SE. Rubella vaccines. Plotkin’s vaccines. Elsevier 2018; pp. 970-1000. doi: 10.1016/B978-0-323-35761-6.00052-3
  88. Ovsyannikova IG, Schaid DJ, Larrabee BR, Haralambieva IH, Kennedy RB, Poland GA. A large population-based association study between HLA and KIR genotypes and measles vaccine antibody responses. PLoS One 2017; 12(2): e0171261. doi: 10.1371/journal.pone.0171261 PMID: 28158231
  89. Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz VS. Twin studies of immunogenicity determining the genetic contribution to vaccine failure. Vaccine 2001; 19(17-19): 2434-9. doi: 10.1016/S0264-410X(00)00468-0 PMID: 11257374
  90. Haralambieva IH, Kennedy RB, Ovsyannikova IG, Whitaker JA, Poland GA. Variability in humoral immunity to measles vaccine: New developments. Trends Mol Med 2015; 21(12): 789-801. doi: 10.1016/j.molmed.2015.10.005 PMID: 26602762
  91. Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. The pathogenesis of Ebola virus disease. Annu Rev Pathol 2017; 12(1): 387-418. doi: 10.1146/annurev-pathol-052016-100506 PMID: 27959626
  92. Jacob ST, Crozier I, Fischer WA II, et al. Ebola virus disease. Nat Rev Dis Primers 2020; 6(1): 13. doi: 10.1038/s41572-020-0147-3 PMID: 32080199
  93. Ebola virus disease 2023. Available from: https://www.who.int/health-topics/ebola/#tab=tab_1
  94. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163(6): 2347-70. doi: 10.1016/S0002-9440(10)63591-2 PMID: 14633608
  95. First vaccine to protect against Ebola 2019. Available from: https://www.ema.europa.eu/en/news/first-vaccine-protect-against-ebola
  96. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response. 2019.
  97. Woolsey C, Geisbert TW. Current state of Ebola virus vaccines: A snapshot. PLoS Pathog 2021; 17(12): e1010078. doi: 10.1371/journal.ppat.1010078 PMID: 34882741
  98. PREVAC Study team. Randomized trial of vaccines for zaire Ebola virus disease. N Engl J Med 2022; 387(26): 2411-24. doi: 10.1056/NEJMoa2200072 PMID: 36516078
  99. Pasin C, Balelli I, Van Effelterre T, et al. Dynamics of the humoral immune response to a prime-boost Ebola vaccine: Quantification and sources of variation. J Virol 2019; 93(18): e00579-19. doi: 10.1128/JVI.00579-19 PMID: 31243126
  100. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 868-71. doi: 10.1126/science.6189183 PMID: 6189183
  101. UNAIDS data 2019. 2019. Available from: https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data
  102. Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of infection: A brief overview. Ann Ist Super Sanita 2010; 46(1): 5-14. doi: 10.1590/S0021-25712010000100002 PMID: 20348614
  103. How is HIV passed from one person to another? 2022. Available from: https://www.cdc.gov/hiv/basics/hiv-transmission/ways-people-get-hiv.html
  104. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral dynamics of acute HIV-1 infection. J Exp Med 1999; 190(6): 841-50. doi: 10.1084/jem.190.6.841 PMID: 10499922
  105. Lucas S, Nelson AM. HIV and the spectrum of human disease. J Pathol 2015; 235(2): 229-41. doi: 10.1002/path.4449 PMID: 25251832
  106. Haynes BF, Wiehe K, Borrow P, et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol 2023; 23(3): 142-58. doi: 10.1038/s41577-022-00753-w PMID: 35962033
  107. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers 2015; 1(1): 15035. doi: 10.1038/nrdp.2015.35 PMID: 27188527
  108. Hsu DC, O’Connell RJ. Progress in HIV vaccine development. Hum Vaccin Immunother 2017; 13(5): 1018-30. doi: 10.1080/21645515.2016.1276138 PMID: 28281871
  109. Huang Y, Follmann D, Nason M, et al. Effect of rAd5-vector HIV-1 preventive vaccines on HIV-1 acquisition: A participant-level meta-analysis of randomized trials. PLoS One 2015; 10(9): e0136626. doi: 10.1371/journal.pone.0136626 PMID: 26332672
  110. Kaur G, Mehra N. Genetic determinants of HIV‐1 infection and progression to AIDS: Immune response genes. Tissue Antigens 2009; 74(5): 373-85. doi: 10.1111/j.1399-0039.2009.01337.x PMID: 19765261
  111. Kaur G, Mehra N. Genetic determinants of HIV‐1 infection and progression to AIDS: Susceptibility to HIV infection. Tissue Antigens 2009; 73(4): 289-301. doi: 10.1111/j.1399-0039.2009.01220.x PMID: 19317737
  112. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273(5283): 1856-62. doi: 10.1126/science.273.5283.1856 PMID: 8791590
  113. Li SS, Gilbert PB, Tomaras GD, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest 2014; 124(9): 3879-90. doi: 10.1172/JCI75539 PMID: 25105367
  114. Li SS, Gilbert PB, Carpp LN, et al. Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 risk in the HVTN 505 HIV vaccine trial. J Virol 2019; 93(21): e02041-18. doi: 10.1128/JVI.02041-18 PMID: 31434737
  115. Davis NA, Crowe JE Jr, Pajewski NM, McKinney BA. Surfing a genetic association interaction network to identify modulators of antibody response to smallpox vaccine. Genes Immun 2010; 11(8): 630-6. doi: 10.1038/gene.2010.37 PMID: 20613780
  116. Davila S, Froeling FEM, Tan A, et al. New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun 2010; 11(3): 232-8. doi: 10.1038/gene.2010.1 PMID: 20237496
  117. Nishida N, Sugiyama M, Sawai H, et al. Key HLA‐DRB1‐DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. Hepatology 2018; 68(3): 848-58. doi: 10.1002/hep.29876 PMID: 29534301
  118. Lin YJ, Lan YC, Huang YC, et al. Effects of cytokine and cytokine receptor gene variation on high anti-HB titers: Following up on Taiwan’s neonatal hepatitis B immunization program. Clin Chim Acta 2012; 413(15-16): 1194-8. doi: 10.1016/j.cca.2012.03.004 PMID: 22484276
  119. Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. Tissue Antigens 2008; 72(3): 211-20. doi: 10.1111/j.1399-0039.2008.01097.x PMID: 18715339
  120. Yucesoy B, Johnson VJ, Fluharty K, et al. Influence of cytokine gene variations on immunization to childhood vaccines. Vaccine 2009; 27(50): 6991-7. doi: 10.1016/j.vaccine.2009.09.076 PMID: 19819209
  121. Ganczak M, Skonieczna-Żydecka K, Drozd-Dąbrowska M, Adler G. Possible impact of 190G > A CCR2 and Δ32 CCR5 mutations on decrease of the HBV vaccine immunogenicity: A preliminary report. Int J Environ Res Public Health 2017; 14(2): 166. doi: 10.3390/ijerph14020166 PMID: 28208753
  122. Pan L, Zhang L, Zhang W, et al. A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations. Hum Mol Genet 2014; 23(8): 2210-9. doi: 10.1093/hmg/ddt586 PMID: 24282030
  123. Png E, Thalamuthu A, Ong RTH, Snippe H, Boland GJ, Seielstad M. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. Hum Mol Genet 2011; 20(19): 3893-8. doi: 10.1093/hmg/ddr302 PMID: 21764829
  124. Wu TW, Chu CC, Ho TY, et al. Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents. Hum Genet 2013; 132(10): 1131-9. doi: 10.1007/s00439-013-1320-5 PMID: 23739870
  125. Martinetti M, De Silvestri A, Belloni C, et al. Humoral response to recombinant hepatitis B virus vaccine at birth: Role of HLA and beyond. Clin Immunol 2000; 97(3): 234-40. doi: 10.1006/clim.2000.4933 PMID: 11112362
  126. Milich DR, Leroux-Roels GG. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003; 2(5): 248-57. doi: 10.1016/S1568-9972(03)00031-4 PMID: 12965175
  127. Hennig BJ, Fielding K, Broxholme J, et al. Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One 2008; 3(3): e1898. doi: 10.1371/journal.pone.0001898 PMID: 18365030
  128. Duan Z, Chen X, Liang Z, et al. Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine. Vaccine 2014; 32(41): 5316-22. doi: 10.1016/j.vaccine.2014.07.064 PMID: 25077417
  129. Ryckman KK, Fielding K, Hill AV, et al. Host genetic factors and vaccine-induced immunity to HBV infection: Haplotype analysis. PLoS One 2010; 5(8): e12273. doi: 10.1371/journal.pone.0012273 PMID: 20806065
  130. Wang Y, Xu P, Zhu D, et al. Association of polymorphisms of cytokine and TLR-2 genes with long-term immunity to hepatitis B in children vaccinated early in life. Vaccine 2012; 30(39): 5708-13. doi: 10.1016/j.vaccine.2012.07.010 PMID: 22824342
  131. Yucesoy B, Talzhanov Y, Johnson VJ, et al. Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations. Vaccine 2013; 31(46): 5381-91. doi: 10.1016/j.vaccine.2013.09.026 PMID: 24075919
  132. Wu TW, Chen CF, Lai SK, Lin HH, Chu CC, Wang LY. SNP rs7770370 in HLA‐DPB 1 loci as a major genetic determinant of response to booster hepatitis B vaccination: Results of a genome‐wide association study. J Gastroenterol Hepatol 2015; 30(5): 891-9. doi: 10.1111/jgh.12845 PMID: 25389088
  133. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 2006; 193(5): 655-63. doi: 10.1086/500144 PMID: 16453260
  134. Dhiman N, Ovsyannikova IG, Cunningham JM, et al. Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes. J Infect Dis 2007; 195(1): 21-9. doi: 10.1086/510596 PMID: 17152005
  135. Haralambieva IH, Ovsyannikova IG, Kennedy RB, et al. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 2011; 29(45): 7883-95. doi: 10.1016/j.vaccine.2011.08.083 PMID: 21875636
  136. Ovsyannikova IG, Haralambieva IH, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum Genet 2011; 130(4): 547-61. doi: 10.1007/s00439-011-0977-x PMID: 21424379
  137. Ovsyannikova IG, Haralambieva IH, Vierkant RA, O’Byrne MM, Jacobson RM, Poland GA. Effects of vitamin A and D receptor gene polymorphisms/haplotypes on immune responses to measles vaccine. Pharmacogenet Genomics 2012; 22(1): 20-31. doi: 10.1097/FPC.0b013e32834df186 PMID: 22082653
  138. Ovsyannikova IG, Salk HM, Larrabee BR, Pankratz VS, Poland GA. Single-nucleotide polymorphism associations in common with immune responses to measles and rubella vaccines. Immunogenetics 2014; 66(11): 663-9. doi: 10.1007/s00251-014-0796-z PMID: 25139337
  139. Dhiman N, Poland GA, Cunningham JM, et al. Variations in measles vaccine–specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J Allergy Clin Immunol 2007; 120(3): 666-72. doi: 10.1016/j.jaci.2007.04.036 PMID: 17560639
  140. White SJ, Haralambieva IH, Ovsyannikova IG, Vierkant RA, O’Byrne MM, Poland GA. Replication of associations between cytokine and cytokine receptor single nucleotide polymorphisms and measles-specific adaptive immunophenotypic extremes. Hum Immunol 2012; 73(6): 636-40. doi: 10.1016/j.humimm.2012.03.015 PMID: 22504412
  141. Omersel J, Karas Kuželički N. Vaccinomics and adversomics in the era of precision medicine: A review based on HBV, MMR, HPV, and COVID-19 vaccines. J Clin Med 2020; 9(11): 3561. doi: 10.3390/jcm9113561 PMID: 33167413
  142. Haralambieva IH, Ovsyannikova IG, Umlauf BJ, et al. Genetic polymorphisms in host antiviral genes: Associations with humoral and cellular immunity to measles vaccine. Vaccine 2011; 29(48): 8988-97. doi: 10.1016/j.vaccine.2011.09.043 PMID: 21939710
  143. Ovsyannikova IG, Haralambieva IH, Vierkant RA, O’Byrne MM, Jacobson RM, Poland GA. The association of CD46, SLAM and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses: A replication study and examination of novel polymorphisms. Hum Hered 2011; 72(3): 206-23. doi: 10.1159/000331585 PMID: 22086389
  144. Dhiman N, Ovsyannikova IG, Vierkant RA, et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: Preliminary results. Vaccine 2008; 26(14): 1731-6. doi: 10.1016/j.vaccine.2008.01.017 PMID: 18325643
  145. Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity. PLoS One 2010; 5(7): e11806. doi: 10.1371/journal.pone.0011806 PMID: 20668555
  146. Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 2008; 121(5): e1091-9. doi: 10.1542/peds.2007-1575 PMID: 18450852
  147. Lambert ND, Haralambieva IH, Kennedy RB, Ovsyannikova IG, Pankratz VS, Poland GA. Polymorphisms in HLA-DPB1 are associated with differences in rubella virus-specific humoral immunity after vaccination. J Infect Dis 2015; 211(6): 898-905. doi: 10.1093/infdis/jiu553 PMID: 25293367
  148. Dhiman N, Haralambieva IH, Kennedy RB, et al. SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics 2010; 62(4): 197-210. doi: 10.1007/s00251-010-0423-6 PMID: 20217072
  149. Ovsyannikova IG, Haralambieva IH, Dhiman N, et al. Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis 2010; 201(2): 207-13. doi: 10.1086/649588 PMID: 20001730
  150. Ovsyannikova IG, Jacobson RM, Vierkant RA, O’Byrne MM, Poland GA. Replication of rubella vaccine population genetic studies: Validation of HLA genotype and humoral response associations. Vaccine 2009; 27(49): 6926-31. doi: 10.1016/j.vaccine.2009.08.109 PMID: 19761839
  151. Ovsyannikova IG, Vierkant RA, Pankratz VS, O’Byrne MM, Jacobson RM, Poland GA. HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine. Vaccine 2009; 27(25-26): 3349-58. doi: 10.1016/j.vaccine.2009.01.080 PMID: 19200828

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2024